Clinical Trial Update: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports results from a Phase 1/2 study evaluating ipilimumab with or without talimogene laherparepvec (T-VEC) in patients with unresected mela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Amgen | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-10-09